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OMO-1 reduces progression and enhances cisplatin efficacy in
a 4T1-based non-c-MET addicted intraductal mouse model for
triple-negative breast cancer
Jonas Steenbrugge 1,2✉, Niels Vander Elst 1, Kristel Demeyere1, Olivier De Wever2,3, Niek N. Sanders2,4, Wim Van Den Broeck5,
Eric Ciamporcero6, Timothy Perera6 and Evelyne Meyer1,2
c-MET is considered a driver of cancer progression, impacting tumor growth and tumor-supporting stroma. Here, we investigated
the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for
triple-negative breast cancer (TNBC). OMO-1 reduced non-c-MET addicted 4T1 tumor progression dose dependently as
monotherapeutic and provided additional disease reduction in combination with cisplatin. At the stromal level, OMO-1 significantly
reduced neutrophil infiltration in 4T1 tumors, promoted immune activation, and enhanced cisplatin-mediated reduction of tumor-
associated macrophages. OMO-1 treatment also reduced 4T1 tumor hypoxia and increased expression of pericyte markers,
indicative for vascular maturation. Corroborating this finding, cisplatin delivery to the 4T1 primary tumor was enhanced upon OMO-
1 treatment, increasing cisplatin DNA-adduct levels and tumor cell death. Although verification in additional cell lines is warranted,
our findings provide initial evidence that TNBC patients may benefit from OMO-1 treatment, even in cases of non-c-MET addicted
tumors.
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INTRODUCTION
The c-MET pathway is known to drive cellular malignant processes
and has been reported as a target for anticancer therapy1–4.
Bound by hepatocyte growth factor (HGF), the receptor tyrosine
kinase c-MET provides necessary survival and migration signals
during embryogenesis2–4. Whilst mutations in this pathway
stimulate the growth and metastasis of some tumors, it also plays
a major role in the tumor stroma. Indeed, HGF/c-MET signaling
stimulates the recruitment of neutrophils5 and can induce the
production of anti-inflammatory cytokines6. Moreover, there have
been clear indications that c-MET is involved in neovascularization
and blood vessel homeostasis6. In the context of triple-negative
breast cancer (TNBC), c-MET is overexpressed in about 52% of
TNBC patient tumors, and high c-MET expression is correlated with
worse disease-free as well as overall survival7,8. These findings
have prompted the clinical testing of c-MET signaling blockers for
TNBC, including ATP-competitive small molecule inhibitors1.
Crizotinib and cabozantinib, for example, showed promising
results in TNBC preclinical models and patients9–12. A recently
developed highly selective ATP-competitive c-MET inhibitor OMO-
1 (formerly referred to as JNJ-38877618, chemical structure:
6-(difluoro(6-(pyridin-4-yl)1,2,4triazolo[4,3-b]pyridazin-3-yl)methyl)
quinoline) has also raised attention as an alternative agent1,13.
More specifically, preclinical studies with OMO-1 showed its
superior inhibitory activity against wild-type c-MET compared to
crizotinib (i.e., 2 versus 11.7 nM IC50)
13. A phase I/II clinical trial
(NCT03138083) evaluated the safety, tolerability, and preliminary
therapeutic efficacy of OMO-1 in c-MET pathway-driven solid
tumors13,14. Nevertheless, the efficacy of OMO-1 in TNBC has not
yet been investigated preclinically.
Here, we evaluated the efficacy of OMO-1 in an innovative 4T1-
based immunocompetent intraductal mouse model for TNBC. In
contrast to the classical fat pad model, the intraductal model more
closely resembles the human disease process as intraductally
inoculated tumors grow from within the mammary ducts and
undergo ductal breakthrough to invade the mammary fat pad
and metastasize to distant organs15–18. The use of immunocom-
petent mice allows to study the possible impact of OMO-1 on
tumor immunology. Moreover, as 4T1 tumors are highly hypoxic
and angiogenic16,18, the use of a 4T1-based model allows the
elucidation of a potential impact of OMO-1 on intratumoral
hypoxia and tumor vasculature.
RESULTS
OMO-1 decreases non-c-MET addicted tumor progression and
has additional therapeutic effects in combination with
cisplatin
Following intraductal inoculation of luciferase-expressing 4T1
tumor cells through the teat canal of syngeneic and lactating
BALB/c mice, primary tumors were allowed to grow for 21 days.
Based on previous studies by our group15–18 and cytokeratin
5 stainings for myoepithelial cells, 4T1 tumor cells remained inside
the mammary ducts surrounded by an intact epithelial barrier
until 7 days post inoculation (p.i.), characteristic for the ductal
carcinoma in situ (DCIS) stage (Fig. 1a). By 21 days p.i., primary
tumors progressed to invasive carcinoma, characterized by tumor
cells that were breaking through the ductal epithelial barrier as
shown by cytokeratin 5 stainings, in order to invade the mammary
fat pad (Fig. 1a). Mice were dosed either with OMO-1 (i.e., OMO-1
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Fig. 1 OMO-1 treatment decreases primary tumor growth in a 4T1-based intraductal model. a Experimental timeline of the study,
including immunohistochemistry for the myoepithelial cell marker cytokeratin 5 on primary tumor paraffin sections at 7 and 21 days p.i. Scale
bar= 50 µm. Mouse body temperature (b) and weight (c) measurements (of the 29 included tumor-bearing mice, 4 mice were treated with
vehicle, 4 mice with 3mg/kg OMO-1, 4 mice with 12.5 mg/kg OMO-1, 3 mice with 25mg/kg OMO-1, 3 mice with cisplatin+ vehicle, 4 mice
with cisplatin+ 3mg/kg OMO-1, 3 mice with cisplatin+ 12.5 mg/kg, and 4 mice with cisplatin+ 25mg/kg OMO-1). d Primary tumor growth
based on tumor volume measurements (n= 7 for vehicle, n= 6 for 25mg/kg OMO-1, cisplatin+ vehicle and cisplatin+ 12.5 mg/kg OMO-1,
n= 8 for all other treatment groups at 39 days p.i.). Insert shows statistically nonsignificant differences in primary tumor volumes between the
randomized treatment groups at the start of treatment (i.e., 21 days p.i.). e Primary tumor growth based on in vivo imaging (measured as total
flux density (p/s/cm2)) (n= same as for tumor volume measurements, except n= 4 for 25mg/kg OMO-1 at 39 days p.i.). Insert shows
statistically nonsignificant differences in total flux density in primary tumors between the randomized treatment groups at the start
of treatment (i.e., 21 days p.i.). f Representative images of the in vivo bioluminescence signals at 39 days p.i. in each treatment group. Data in
b–e are presented as the means ± standard error of the mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001.
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monotherapy) or with the OMO-1 vehicle as control, both
administered orally 2×/day (bis in die, b.i.d.) for a period of
18 days. To investigate the influence of OMO-1 on chemotherapy,
cisplatin was administered every 5 days intraperitoneally (i.p.) for a
period of 18 days to a group of tumor-bearing mice in
combination with b.i.d. oral administration of either OMO-1 (i.e.,
cisplatin+OMO-1) or the OMO-1 vehicle (i.e., cisplatin+ vehicle)
as control. Treatment with OMO-1 did not alter body temperature,
either as monotherapy or in combination with cisplatin (Fig. 1b).
OMO-1 monotherapy also did not alter body weight (Fig. 1c). On
the other hand, treatment with cisplatin with or without OMO-1
decreased body weight at the endpoint (i.e., 39 days p.i.)
compared to vehicle (Fig. 1c), but only the decrease in the
cisplatin+ 3mg/kg and 12.5 mg/kg OMO-1 combination treat-
ment groups was statistically significant. Of note, all mice showed
weight loss in the first week p.i. due to decreased milk production
after weaning of the pups. At the start of treatment (i.e., 21 days
p.i.), baseline tumor growth did not statistically differ between the
randomized treatment groups based on tumor volume measure-
ments as well as on in vivo imaging. Yet, both techniques
identified a significant and dose-dependent reduction in primary
tumor progression with OMO-1 monotherapy at 39 days p.i., (i.e.,
following 18 days of treatment) (Fig. 1d–f). Although the cisplatin
and OMO-1 combination-treated tumors were smaller than
cisplatin+ vehicle-treated tumors, this reduction did not reach
significance possibly because of the small group sizes.
Ki67 stainings and index calculations identified a significant
decrease in cellular proliferation of primary tumors treated with
12.5 and 25mg/kg OMO-1 monotherapy compared to vehicle
treatment. This decrease was more pronounced both with
cisplatin+ vehicle and cisplatin+OMO-1 combination treatment
(Supplementary Fig. 1a). Importantly, cisplatin+ 25mg/kg OMO-1
combination treatment significantly reduced the Ki67 staining
compared to cisplatin+ vehicle treatment (Supplementary Fig.
1a). To identify whether c-MET addiction of 4T1 tumor cells and
their concomitant sensitivity to c-MET blockade could explain the
reduction in cell proliferation upon OMO-1 treatment, we
evaluated c-MET expression in 4T1 primary tumors. Yet, the
expression of c-MET by western blot analysis was limited, based
on two independent antibodies on the same blot, showing only a
very faint (nonspecific) band between 130 and 180 kDa or
between 100 and 130 kDa (expected molecular weights are
145 kDa for the mature c-MET β-subunit and 170 kDa for the
pro-c-MET) in both treated and untreated primary tumor samples
(Supplementary Fig. 1b). Corroborating the ex vivo western
blotting, 4T1 cells showed limited c-MET expression in vitro
(Supplementary Fig. 1b). Western blotting on lysates of cultured
4T1 cells following 48 h treatment with either OMO-1 or dimethyl
sulfoxide (DMSO, i.e., OMO-1 vehicle solution) in combination with
or without cisplatin showed similar phosphorylated Akt and p44/
42 MAPK (Erk1/2) levels in all in vitro treatment conditions
(Supplementary Fig. 2a). In contrast, the c-MET amplified human
non-small cell lung carcinoma cell line NCI-H441 serving as
positive control showed strong and dose-dependent reduction in
phosphorylated c-MET levels as well as in phosphorylated
downstream effectors Gab2, Akt, MEK1/2, and p42/44 MAPK
(Erk1/2) upon OMO-1 treatment (Supplementary Fig. 2b). In vitro
4T1 tumor cell growth was also unaffected by 48 h treatment with
OMO-1 compared to DMSO control as determined by neutral red
uptake assay, which is to be expected from a non-c-MET addicted
cell line (Supplementary Fig. 3a). Only cisplatin treatment
significantly inhibited in vitro cellular growth and OMO-1 did
not have an additive treatment effect. Ki67 immunocytochemical
stainings and the proliferation index of the treated 4T1 tumor cell
cultures confirmed these findings (Supplementary Fig. 3b).
Immunocytochemical stainings for cleaved caspase 3 showed that
the decreased in vitro cellular growth with cisplatin treatment was
associated with an increase in cell death (Supplementary Fig. 3b).
Analysis of 4T1 bioluminescence in isolated axillary lymph
nodes and lungs of the tumor-bearing mice identified a significant
reduction in metastases with cisplatin, either in combination with
or without OMO-1, compared to vehicle treatment (Supplemen-
tary Fig. 4a). Of note, the intensity of bioluminescent signals was
higher in lungs compared to axillary lymph nodes in vehicle-
treated mice, which verifies the lungs as primary metastatic site
for 4T1 cells. Hematoxylin and eosin (H&E) histology (Supplemen-
tary Fig. 4b) and Ki67 staining (Supplementary Fig. 5) identified
infiltrating and proliferative tumor cells based on morphology and
showed that the cisplatin+ 25mg/kg OMO-1 combination treat-
ment induced complete elimination of the metastases in axillary
lymph nodes and lungs compared to cisplatin+ vehicle treat-
ment. Bioluminescent signals were also detected in the liver of
tumor-bearing mice and were significantly reduced with cisplatin
treatment (Supplementary Fig. 4a). H&E histology showed cellular
infiltration from the vasculature into the liver tissue (Supplemen-
tary Fig. 4b) and Ki67 stainings further verified the presence of
proliferative cells, which significantly reduced with OMO-1
compared to vehicle treatment either in combination with or
without cisplatin (Supplementary Fig. 6). Interestingly, the Ki67+
proliferating cells were not identified as tumor cells based on their
negative pan-cytokeratin staining, but as myeloid cells based on
their positive CD11b staining (Supplementary Fig. 6). Quantifica-
tion of the CD11b stainings in liver tissue of the different
treatment groups showed a significant reduction in myeloid cell
content with OMO-1 treatment in combination with or without
cisplatin (Supplementary Fig. 6), indicative for a decrease in
disease progression and myeloid cell-mediated immunosuppres-
sion. Of note, the observed bioluminescent signals in the liver are
likely not derived from the proliferative myeloid cells, but rather
background from 4T1 cells in blood that excessively flows through
and can be contained in the liver.
OMO-1 decreases neutrophil infiltration, induces immune
stimulation, and in combination with cisplatin reduces tumor-
associated macrophages (TAMs)
Splenomegaly has been associated with 4T1 tumor progression
and leukemoid reactions15,16,18–21. Based on spleen weights,
tumor-bearing mice receiving vehicle suffered from severe
splenomegaly (Supplementary Fig. 7a). Cisplatin either with or
without OMO-1 significantly reduced splenomegaly compared to
vehicle treatment, i.e., to near healthy spleen weights, but OMO-1
showed no additional effect compared to cisplatin+ vehicle
treatment (Supplementary Fig. 7a).
Chitinase 3-like 1 (CHI3L1) and lipocalin 2 (LCN2) have been
utilized as immune-related biomarkers for disease progression in
breast cancer patients22–24 and in the 4T1-based immunocompe-
tent intraductal mouse model for TNBC15,16,18. Similar to the
splenomegaly, CHI3L1 and LCN2 levels were reduced in primary
tumors, sera, and spleens upon cisplatin treatment either with or
without OMO-1 compared to vehicle treatment (Supplementary
Fig. 7b–d). Again, OMO-1 showed no additional effect compared
to cisplatin+ vehicle.
The levels of a panel consisting of 11 selected cytokines were
subsequently measured in primary tumor lysates to provide a
broader view of the local immune responses in the treated mice.
In primary tumors, OMO-1 monotherapy significantly reduced the
levels of macrophage inflammatory protein (MIP)-2, a major
neutrophil chemoattractant, compared to vehicle treatment
(Supplementary Fig. 8a). Interestingly, primary tumor MIP-2 levels
also significantly decreased with cisplatin+OMO-1 combination
but not with cisplatin+ vehicle treatment, both compared to
vehicle treatment (Supplementary Fig. 8a). Cisplatin treatment had
a profound immunological effect by significantly reducing the
levels of the primary tumor cytokines B-cell activating factor
(BAFF) and interleukin (IL)-1β compared to vehicle treatment
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(Supplementary Fig. 8a). The levels of eight other cytokines, i.e.,
granulocyte colony-stimulating factor (G-CSF), interferon (IFN)-γ,
IL-4, IL-6, IL-10, monocyte chemoattractant protein (MCP)-1, tumor
necrosis factor (TNF)-α, and transforming growth factor (TGF)-β1,
showed no statistically significant changes with either of the
treatments.
Protein array analysis highlighted 11 additional protein markers
that were significantly altered in primary tumor lysates upon
OMO-1 monotherapy and, in some cases, also upon cisplatin+
OMO-1 combination therapy (Supplementary Fig. 8b). Immune-
associated proteins including CD40, C-X3-C motif chemokine
ligand 1, IL-1ra, IL-12 p40, and regenerating family member 3
gamma showed significantly increased levels in the 25mg/kg
OMO-1-treated compared to vehicle treatment group, indicating
that OMO-1 induced stimulation of the immune system (Supple-
mentary Fig. 8c). OMO-1 further induced a tumor suppressive
effect based on enhanced osteoprotegerin and Wnt1-inducible
signaling pathway protein 1 (WISP-1) levels (Supplementary Fig.
8c). WISP-1 was not OMO-1-specific as cisplatin+ vehicle treat-
ment induced a similar enhancement. The four remaining proteins
are linked to vascular stability and integrity, which impacts tumor
escape and immune infiltration. More specifically, treatment with
OMO-1 significantly increased the production of endoglin,
fibroblast growth factor (FGF)-1, intercellular adhesion molecule
(ICAM)-1, and matrix metalloproteinase (MMP)-3 compared to
vehicle treatment (Supplementary Fig. 8c). In combination with
cisplatin, OMO-1 induced a significant increase in endoglin and
FGF-1 compared to vehicle (Supplementary Fig. 8c).
Immunohistochemical staining allowed further visualization of
the immune components of the TME in the different treatment
groups. OMO-1 in combination with or without cisplatin
significantly reduced myeloid cell numbers in primary tumors
compared to vehicle treatment based on CD11b stainings (Fig. 2).
Expression of the CD163 TAM marker significantly decreased in
primary tumors treated with cisplatin+OMO-1 combination
treatment, when compared to vehicle and cisplatin+ vehicle
treatment (Fig. 2). Expression of the Ly6G tumor-associated
neutrophil (TAN) marker significantly decreased in primary tumors
treated with 12.5 and 25mg/kg OMO-1 monotherapy and in the
cisplatin+OMO-1 combination groups, but was not observed
with cisplatin+ vehicle treatment when compared to vehicle
treatment (Fig. 2). This observation corroborates the MIP-2 levels
observed upon cytokine profiling in primary tumors (Supplemen-
tary Fig. 8a). Expression of the CD8a cytotoxic T-cell marker did not
significantly differ between the treatment groups (Fig. 2). Similarly,
expression of the granzyme B T-cell activity marker and immune
checkpoint proteins programmed death (PD)-1 and cytotoxic
T-lymphocyte antigen (CTLA)-4 did not significantly decrease with
either treatment based on immunohistochemistry (Supplementary
Fig. 9a) or on protein levels in tumor lysates (Supplementary
Fig. 9b). These observations corroborate the unchanged T-cell-
associated IFN-γ and TNF-α primary tumor levels with either
treatment based on cytokine profiling (Supplementary Fig. 8a).
OMO-1 decreases hypoxia and is associated with increased
pericyte markers in primary tumors
4T1 tumor cells have been shown to grow aggressively and form
highly hypoxic primary tumors in the immunocompetent intra-
ductal mouse model for TNBC16,18. To investigate whether OMO-1
treatment impacts 4T1 tumor hypoxia concomitant with the
reduced primary tumor growth, pimonidazole hydrochloride was
administered before sacrifice. Pimonidazole is a 2-nitroimidazole-
based agent that forms adducts with thiol groups in hypoxic cells
at oxygen levels below 10mmHg25,26. An FITC-conjugated anti-
body that specifically recognizes pimonidazole adducts allows to
visualize poorly oxygenated regions in histological sections of
primary tumors. The amount of pimonidazole adduct staining has
been described as proportional to the level of hypoxia in primary
tumors26. Detectable levels of pimonidazole adducts significantly
decreased upon monotherapy with 25 mg/kg OMO-1 compared
to vehicle treatment (Fig. 3). Moreover, when combined with
cisplatin, OMO-1 established a significant reduction in pimonida-
zole adduct staining compared to cisplatin+ vehicle treatment.
Staining for carbonic anhydrase 9 (CAIX), a hypoxia-associated
enzyme27,28, corroborated these findings (Fig. 3). Both pimonida-
zole and CAIX stainings identified that cisplatin+ vehicle treat-
ment did not significantly decrease tumor hypoxia compared to
vehicle treatment, suggesting that the effects of OMO-1 correlate
with its activity on the tumor vasculature and oxygenation.
Interestingly, OMO-1 monotherapy did not alter primary tumor
levels of the angiogenesis biomarker vascular endothelial growth
factor (VEGF). Only cisplatin treatment in combination with 3 mg/
kg OMO-1 significantly decreased the primary tumor VEGF levels
compared to vehicle treatment (Fig. 3b). Serum levels of Tie-2, a
biomarker for VEGF inhibition29, stainings for the endothelial
cell marker CD31 and CD31+ vessel counts on primary tumor
sections corroborated these VEGF results with significant reduc-
tion upon cisplatin treatment (Figs. 3c and 4). Of note, whereas
CD31+ stainings and vessel counts decreased in all cisplatin-
treated groups, serum Tie-2 levels only significantly decreased in
the cisplatin+ vehicle and cisplatin+ 12.5 mg/kg OMO-1 group.
Overall, these results identify that OMO-1 does not alter hypoxia
via the modulation of vascular factors and vascular formation in
4T1 primary tumors.
The reduction in tumor hypoxia by OMO-1 may alternatively be
explained by increased pericyte coverage of tumor vasculature,
an indicator of blood vessel maturation, resulting in increased
tumor oxygenation and vessel perfusion30,31. To this end, positive
staining for c-MET in the vascular bed was first verified on primary
tumor sections (Supplementary Fig. 10a). OMO-1 treatment did
not influence the vascular expression of c-MET in primary tumors
based on qualitative assessment of this immunohistochemical
staining (Supplementary Fig. 10a). In line with a potential OMO-1-
mediated vessel normalization, stainings for α-smooth muscle
actin (SMA) (Fig. 4) and platelet-derived growth factor receptor
(PDGFR)-β (Supplementary Fig. 10b), two established pericyte
markers27,28, dose dependently increased in primary tumors
upon OMO-1 monotherapy and cisplatin+OMO-1 combination
treatment compared to vehicle treatment. Double staining
immunohistochemistry for colocalization of CD31 and α-SMA
and subsequent manual counting confirmed the dose-dependent
increase in vascular pericytes upon OMO-1 treatment (Fig. 4).
Pericyte coverage is intricately linked to the family of
angiopoietins (Ang), with Ang-1 and Ang-2 being the most
influential factors30,31. Ang-1 is reported to increase pericyte
survival through activation of Tie-2 expression on endothelial cells
as well as pericytes30–32. Ang-2 on the other hand is reported to
counteract the vascular stabilization effect of Ang-1 by competi-
tively binding to Tie-230–32. As we hypothesized that the increased
pericyte abundance in primary tumors may be explained by an
imbalance between Ang-1 and -2, the primary tumor levels of
both Ang family members were determined. Stainings for Ang-1 in
primary tumors significantly increased upon treatment with 12.5
and 25mg/kg OMO-1 compared to vehicle (Supplementary Fig.
10b). Cisplatin+ 12.5 mg/kg OMO-1- and cisplatin+ 25mg/kg
OMO-1-treated mice also showed increased Ang-1 positivity in
primary tumors compared to cisplatin+ vehicle-treated mice
(Supplementary Fig. 10b). In contrast, primary tumor levels of
Ang-2 were not affected by either treatment, based on western
blot and enzyme-linked immunosorbent assay (ELISA) measure-
ments (Supplementary Fig. 11a, b). In addition, primary tumor
Tie-2 levels were measured through ELISA and were also found to
be similar in all treatment groups (Supplementary Fig. 11c).
As tumor cells have been, in certain cases, reported to resemble
pericytes through a process referred to as epithelial-to-pericyte
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Fig. 2 OMO-1 impacts tumor infiltrating neutrophils and immunosuppressive macrophages in a 4T1-based intraductal model.
Immunohistochemistry for CD11b (pan-myeloid cells), CD163 (tumor-associated macrophages), Ly6G (neutrophils), and CD8a (cytotoxic
T-cells) on paraffin sections of primary tumors from the different treatment groups at 39 days p.i. (n= 8; 2 slides per treatment group for each
marker with 4 images per slide). Scale bars= 50 µm. Data are presented as the means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 3 OMO-1 treatment reduces tumor hypoxia without affecting vascular formation in a 4T1-based intraductal model.
a Immunohistochemistry for the hypoxia markers pimonidazole and CAIX on paraffin sections of primary tumors from the different
treatment groups at 39 days p.i. (n= 8; 2 slides per treatment group for each marker with 4 images per slide). Pimonidazole adducts are
identified through FITC fluorescence and DAPI identifies cellular nuclei through blue fluorescence. Scale bars= 50 µm. b VEGF levels in
primary tumors from the different treatment groups at 39 days p.i. (n= 5 for vehicle and cisplatin+ vehicle, n= 4 for 25 mg/kg OMO-1 and
cisplatin+ 12.5 mg/kg OMO-1, n= 6 for all other treatment groups). c Tie-2 levels in serum from the different treatment groups at 39 days p.i.
(n= 3 for vehicle, cisplatin+ vehicle and cisplatin+ 3mg/kg OMO-1, n= 2 for 25 mg/kg OMO-1, cisplatin+ 12.5 mg/kg OMO-1, and cisplatin
+ 25mg/kg OMO-1, n= 4 for all other treatment groups). Data are presented as the means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 4 OMO-1 treatment increases vascular pericytes in primary tumors of a 4T1-based intraductal model. Immunohistochemistry for the
endothelial cell marker CD31 and the pericyte marker α-SMA and double staining immunohistochemistry for CD31 and α-SMA on paraffin
sections of primary tumors from the different treatment groups at 39 days p.i. (n= 8; 2 slides per treatment group for each marker with 4
images per slide). CD31+ vessels were manually counted on 20× magnified microscopic images. The proportion of α-SMA-covered CD31+
vessels among total counted CD31+ vessels was also determined on 20× magnified microscopic images. Scale bars= 50 µm. Data are
presented as the means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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transition (EPT)33,34, it was investigated whether 4T1 tumor cells
were able to express any pericyte markers upon OMO-1 treatment.
Yet, western blotting with lysates from in vitro cultured and 48-h-
treated 4T1 cells did not detect expression of α-SMA and PDGFR-β
(Supplementary Fig. 11d).
OMO-1 increases cisplatin-induced cell death through
enhanced drug delivery
Based on the potential increase in pericyte coverage upon OMO-
1 treatment, as suggested by the selective increase in pericyte
markers, we further hypothesized that the delivery of cisplatin to
primary tumors could also be increased. Cisplatin DNA-adduct
positivity in primary tumors increased upon OMO-1 treatment in
a dose-dependent manner, being significantly higher with
cisplatin+ 12.5 mg/kg OMO-1 and cisplatin+ 25 mg/kg OMO-1
combination treatment compared to cisplatin+ vehicle treat-
ment (Fig. 5a). As this increased cisplatin delivery would result in
increased cell death within the primary tumors, the levels of the
active apoptotic primary tumor biomarker cleaved caspase 3
were determined. Western blotting and immunohistochemistry
both demonstrated an increase of cleaved caspase 3 levels in
primary tumor lysates, which was OMO-1 dose dependent
(Fig. 5a, b). More specifically, cleaved caspase 3 levels were
significantly higher in cisplatin+ 25 mg/kg OMO-1-treated
primary tumors compared to cisplatin+ vehicle-treated primary
tumors.
DISCUSSION
One strategy to tackle cancer is by inhibiting pathways that
increase tumor cell survival, proliferation, and migration such as
the HGF/c-MET pathway, which is currently being investigated in
multiple cancer types1–4. Although c-MET inhibition as anticancer
strategy has provided promising preliminary results, there is still a
need for both more effective and selective c-MET inhibitors which
could then be combined with other treatment regimens such as
chemotherapy or immunotherapy7,35. In the current proof-of-
concept study, the novel, potent, and selective c-MET inhibitor
OMO-1 was evaluated in the context of TNBC using a validated
4T1-based immunocompetent intraductal mouse model.
Oral treatment with OMO-1 was well tolerated, but body
weights decreased upon cisplatin treatment either alone or in
combination with OMO-1. Cisplatin chemotherapy is known to
cause gastro-intestinal problems which ultimately result in
decreased body weight36. Although cisplatin+ 3mg/kg OMO-1
and cisplatin+ 12.5 mg/kg OMO-1 combination treatment
resulted in the lowest, yet significant, decrease in body weight
compared to vehicle and OMO-1 monotherapy, it is unlikely that
OMO-1 induced a higher toxicity in combination with cisplatin.
Indeed, mice treated with cisplatin in combination with the
highest dose of OMO-1 had a similar body weight compared to
mice treated with cisplatin+ vehicle.
OMO-1 monotherapy induced a significant decrease in tumor
progression and proliferation at the invasive edge, providing an
additional treatment effect when combined with cisplatin, which
strongly indicates a potential benefit for combination therapy in a
clinical setting. Metastases were verified in axillary lymph nodes
and lungs with OMO-1 treatment again providing an added
metastatic reduction in combination with cisplatin. Liver tissue did
not contain metastases, but showed an abundance of proliferative
myeloid cells, which decreased upon treatment with OMO-1.
Indeed, this is likely an indication for 4T1-stimulated extramedul-
lary hematopoiesis in the liver and is known to drive disease
progression and immunosuppressive activity37,38. Although in
contrast to previous reports39,40, very low c-MET expression was
detectable in in vitro 4T1 cell lysates as well as in vivo primary
tumor lysates on western blot (and immunohistochemistry). In line
with this observation, OMO-1-mediated c-MET inhibition also did
not affect phosphorylation of known downstream c-MET effectors
Akt and p44/42 MAPK (Erk1/2) in 4T1 cell lysates nor 4T1 cell
growth in vitro. Consequently, as the progression of the 4T1 cell
line used in our study is not addicted to c-MET signaling, our data
suggest that OMO-1 does not reduce in vivo 4T1 tumor
progression solely by targeting the mammary tumor cells.
At the immunological level, OMO-1 had an inhibitory effect on
neutrophil infiltration in primary tumors. Such TAN blockade by
c-MET inhibitors has been proposed to be detrimental because
of the antitumoral properties attributed to TANs5. However, it
has also been reported that TANs can be immunosuppressive—
albeit in response to immunotherapy—and that immunother-
apeutic efficacy is improved when neutrophil recruitment into
tumors is impaired by c-MET inhibition41. Other studies have
also highlighted a critical role for neutrophils in stimulating
(breast) cancer progression42–45. In line with the hypothesis
of a more immune activated TME, OMO-1 treatment induced
enhanced immunostimulatory and tumor suppressive markers
in primary tumor lysates. Moreover, in combination with
cisplatin, OMO-1 provided a significant reduction in TAM-
mediated immunosuppression.
The reduction in tumor hypoxia is potentially an additional
antitumor activity of OMO-1. Indeed, hypoxia has been associated
with poor prognosis and known to drive metastases46. Our data
show that the OMO-1-mediated hypoxia reduction was not only
due to a decrease in primary tumor growth but rather to a direct
effect on the tumor vasculature. c-MET and its ligand HGF are
intricately linked to angiogenesis by cooperating in VEGF/VEGFR
signaling1,47. Moreover, c-MET has been found to be upregulated
and in an activated state upon hypoxic conditions mediated
by VEGFR inhibitors and pericyte loss in breast cancer models,
including the 4T1 fat pad model48. Several studies have also
reported that a combined VEGFR/c-MET inhibition reduced the
angiogenic response in primary tumors and effectively decreased
tumor progression49–51. Since many of the c-MET inhibitors initially
in clinical development were reported to be nonselective, binding
other receptor tyrosine kinases including VEGFR, this can at least
in part account for their therapeutic effectiveness7. In marked
contrast, OMO-1 treatment did not impact tumor angiogenesis,
highlighting the superior selectivity of OMO-1 and indicating that
an alternative mechanism probably underlies the hypoxia reduc-
tion in OMO-1-treated primary tumors.
Healthy blood vessels are lined by pericytes, which are
responsible for vascular integrity and maturation. The leakiness
of tumor blood vessels leads to increased interstitial pressure,
hypoxia, impairs the delivery of therapeutics to the tumor, and
stimulates metastasis as tumor cells are able to escape through
these gaps in the vascular wall52. Normalization of the tumor
vasculature by increasing pericyte coverage of the vascular wall
can ameliorate these detrimental conditions52–54, and we
hypothesize that OMO-1 could play a role in this process. In line
with our hypothesis, the vascular bed was identified as a potential
target for c-MET inhibition based on its detectable expression of
c-MET in primary tumor sections. The increase in α-SMA+ pericytes
covering CD31+ vessels upon c-MET inhibition by OMO-1 further
verified OMO-1 treatment as indeed being dose dependently
associated with vascular normalization. Consequently, cisplatin
delivery was enhanced upon OMO-1 treatment, in turn leading
to enhanced tumor cell death. Moreover, protein array analysis
showed significant upregulation of four vascular integrity-
associated proteins in primary tumor lysates of OMO-1-treated
mice. More specifically, endoglin as a constituent of the TGF-β
receptor complex in endothelial cells regulates interaction with
pericytes55,56, FGF-1 as a heparin binding growth factor produced
by endothelial cells, pericytes, and fibroblasts may mediate
vascular maturation through regulation of vascular cadherin and
integrin expression57, ICAM-1 as a vascular component for
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leukocyte infiltration regulates blood vessel permeability58, and
MMP-3 as a pericyte-derived enzyme mediates extracellular matrix
degradation for pericyte invasion59. Our data further suggest an
imbalance between Ang-1 and -2 levels in favor of Ang-1, pericyte
survival, and vessel normalization upon OMO-1 treatment in
primary tumors. It should be emphasized that increased pericyte
coverage and Ang-1 levels are unprecedented results for a c-MET
inhibitor. Kobayashi et al. reported that HGF stimulates migration
of smooth muscle cells/pericytes toward endothelial cells in
response to Ang-160. Liu et al. reported that c-MET is expressed in
smooth muscle cells and pericytes and may be involved in
pericyte migration to stabilize new blood vessels in atherosclerotic
lesions61. Consequently, c-MET inhibition should rather attenuate
pericyte recruitment and the likely vessel normalization with
OMO-1 treatment is presumably due to other and/or compensa-
tory mechanisms. EPT of tumor cells may provide an alternative
explanation for the observed normalization effect. Tumor cells that
are prone to spontaneous epithelial-to-mesenchymal transition
can phenotypically and functionally resemble pericytes and
thereby contribute to vascular stability and sustained tumor
growth33,34. In line with this EPT concept, mesenchymal Hs578
TNBC cells have been reported to establish pericyte properties
through expression of pericyte markers including α-SMA and
PDGFR-β62. Yet, 4T1 cells treated with OMO-1 with or without
cisplatin did not express pericyte markers, suggesting that EPT is
unlikely to be responsible for the increase in α-SMA and PDGFR-β
positivity seen in our study. Therefore, the underlying mechanism
(s) for the suggested vessel maturation remain to be elucidated.
In conclusion, our proof-of-concept study establishes OMO-1 as
a potent and selective c-MET inhibitor with highly beneficial
therapeutic effects as monotherapy and in combination with
chemotherapy (cisplatin) in a 4T1-based immunocompetent
intraductal mouse model for TNBC (Fig. 6). More specifically, we
unequivocally demonstrate that OMO-1 treatment: (1) reduces
Fig. 5 OMO-1 treatment increases cisplatin-mediated cell death in primary tumors of a 4T1-based intraductal model. a Immunohis-
tochemistry for cisplatin DNA-adducts and the cell death marker cleaved caspase 3 on paraffin sections of primary tumors at 39 days p.i. treated
with cisplatin+ vehicle and cisplatin + OMO-1 (n= 8; 2 slides per treatment group for each marker with 4 images per slide). Black scale bars=
50 µm, red scale bars= 20 µm. b Western blot for cleaved caspase 3 levels and GAPDH control levels in lysates of primary tumors at 39 days
p.i. treated with cisplatin+ vehicle and cisplatin+OMO-1 (n= 3 for each treatment group). Data are presented as the means ± SEM. **P < 0.01,
***P < 0.001.
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malignant progression and provides additional antitumor effects
to cisplatin in a model that is not c-MET oncogene addicted; (2)
induces immunostimulatory and tumor suppressing expression
profiles, further characterized by a favorable TME with significantly
reduced numbers of TAMs in combination with cisplatin; and (3)
reduces hypoxia, increases cisplatin delivery, and subsequent cell
death in primary tumors potentially through vessel normalization.
Future studies are warranted to validate our results in additional
(TNBC) cell lines and to further delineate the mechanisms that
underly the observed therapeutic efficacy of OMO-1.
METHODS
4T1 cell culture
4T1-luc mammary tumor cells that constitutively express the firefly
luciferase gene and resemble the metastases observed in human TNBC
(estrogen receptor-negative, progesterone receptor-negative, and human
epidermal growth factor receptor 2-negative)63,64 were a kind gift from
Prof. Clare Isacke (Breakthrough Breast Cancer Research Centre, London,
UK). The cells were cultured at passage 8 in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 μg/ml streptomycin (Thermo Fisher Scientific,
Waltham, MA, USA) in culture flasks at 37 °C and 5% CO2. Cell cultures were
routinely checked for mycoplasma contamination using a mycoplasma
detection kit (PlasmoTestTM; Invivogen, San Diego, USA). After washing
with phosphate buffered saline (PBS) to remove dead particles, the cells
were harvested using 0.25% trypsin-ethylenediaminetetraacetic acid
(EDTA) (Sigma-Aldrich, Overijse, Belgium), washed through centrifugation
(805 × g for 5 min), and resuspended in PBS. A Bürker chamber was used
for counting of the cell numbers.
Neutral red uptake assay on treated 4T1 cell cultures
4T1-luc cells at passage 12–13 were cultured at 3 × 104 cells/ml in slide
chambers (for immunocytochemistry) or in 24-well plates (for neutral red
uptake assay and western blot analysis). After 24 h of incubation in 24-well
plates and 48 h in slide chambers, when cell cultures reached 70%
confluency, cells were treated with either DMSO (i.e., OMO-1 vehicle
solution), 300 nM, 1 μM, or 3 μM OMO-1 in combination with or without
cisplatin (Merck Millipore, Darmstadt, Germany). Cisplatin was dissolved in
0.9% sodium chloride solution (Sigma-Aldrich) and administered to the cell
cultures at 2 μg/ml (for immunocytochemistry, neutral red uptake assay,
and western blot analysis).
Neutral red uptake assays for estimation of cell viability/cytotoxicity
were performed on cell cultures in 24-well plates following 48 h treatment.
Untreated control wells were included, containing no cells (only culture
medium) to correct possible absorption of neutral red to the plastic.
Neutral red medium (0.33%, Sigma-Aldrich) was diluted 1:10 in colorless
culture medium (without phenol red) and filtered using a 0.22 μm filter to
remove precipitated dye crystals. Culture medium was aspirated from the
24-well plates and rinsed with culture medium without phenol red. One
milliliter of the diluted neutral red medium (final concentration: 0.033%)
was added to each well containing treated cells. After incubation of the
plate for 2 h at 37°C and 5% CO2, neutral red medium was aspirated and
the cells were rinsed with 300 μl PBS/well. Neutral red was extracted from
the cells by adding 1ml neutral red destaining solution per well and
shaking the well plate rapidly on a plate shaker for at least 10 min. Finally,
150 μl of each 24-well plate was transferred to a 96-well plate. After
removing air bubbles, the absorbances of neutral red extracts were
measured at 540 nm on a microplate reader.
Intraductal inoculations with 4T1 cells
Animal experiments were conducted according to Good Scientific Practice
principles and approved by the Ethical Committee (EC) of the Faculty of
Veterinary Medicine, Ghent University (EC 2018-37 and amendment EC
2018-65). In order to obtain full lactation, 8-week-old female BALB/c mice
were mated with 8-week-old male BALB/c mice (both obtained from
Envigo, Horst, The Netherlands) and pups were weaned 12–14 days post
parturition. Lactating females were intraductally inoculated through the
mammary teat canal of the third mammary gland pair 1 h after weaning
using a 32-gauge blunt needle with 5 × 104 4T1-luc cells suspended in a
100 μl mixture of 1:10 PBS and Matrigel® (Corning, Bedford, MA, USA). All
materials used were precooled to avoid coagulation of the Matrigel®.
A mixture of oxygen and isoflurane (2–3%) was used for inhalational
anesthesia of the mice and a bolus of PBS-diluted Vetergesic (i.e.,
buprenorphine 10 µg/kg, Val d’Hony-Verdifarm NV, Belgium) was adminis-
tered i.p. as analgesic prior to any surgical intervention.
Treatment of tumor-bearing mice
As a positive control treatment, cisplatin was dissolved under sterile
conditions in 0.9% sodium chloride solution in a dark recipient and 100 µl
was administered i.p. every 5 days at 6 mg/kg. OMO-1 vehicle solution was
freshly prepared every 3 days. In order to prepare the OMO-1 vehicle
solution, methyl cellulose with viscosity 400 cPs (Alfa Aesar, Massachusetts,
USA) was slowly brought in boiling dH2O at 0.5% (w/v) while stirring on a
magnetic stirrer. The solution was subsequently sterilized in an autoclave
and cooled to room temperature (RT) overnight (ON) while stirring on a
Fig. 6 Working model for OMO-1 treatment in a 4T1-based intraductal model. Key findings upon treatment with OMO-1 are highlighted.
More specifically, tumor growth is reduced, neutrophil influx is impaired (decreased MIP-2 levels and Ly6G positivity), and antitumor responses
are more pronounced (increased levels of immunostimulatory and tumor suppressive proteins, decreased CD163 positivity). Leaky vessels
are normalized to enhance the blood flow to the primary tumor (increased α-SMA, PDGFR-β, and Ang-1 positivity as well as enhanced α-SMA-
covered CD31+ vessels), which in turn reduces tumor hypoxia and increases the delivery of chemotherapeutics (increased cisplatin DNA-
adducts and cleaved caspase 3 levels).
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magnetic stirrer. Before usage, the pH of the 0.5% methyl cellulose solution
was adjusted to 2.5–3.5 using 1N HCl. The OMO-1 treatment solution was
freshly prepared every day. In order to prepare it, the required volume of
OMO-1 was weighed, 0.1 % (v/v) Tween-80 (Sigma-Aldrich) was added, and
the contents were triturated to form a uniform mix using an appropriate
pestle (pestle and microtube combo, VWR, Oud-Heverlee, Belgium). Next,
25% of the required volume of 0.5% methyl cellulose at pH 2.5–3.5 (i.e., the
OMO-1 vehicle solution) was added and the mixture was triturated.
Another 25% required volume of 0.5% methyl cellulose was then added for
trituration and finally the remaining 50% of 0.5% methyl cellulose. The
OMO-1 treatment solution was adjusted to pH 2.5–3.5, vortexed, and
stored at 4 °C before usage. A stainless steel oral gavage needle was used
to administer 100 µl of the OMO-1 treatment solution orally 2×/day (b.i.d.)
from 21 days p.i. until 39 days p.i. at 3 mg/kg (low), 12.5 mg/kg (medium),
or 25mg/kg (high) concentration and the solution was vortexed between
every dosing.
Analysis of primary tumor growth and metastasis progression
The health of the animal was monitored weekly through measurement of
the body weight (using a digital weighing scale) and body temperature
(using a rectal temperature probe). Primary tumor volume was determined
weekly as a measurement of primary tumor growth using a digital caliper.
In vivo imaging of the 4T1-luc-derived bioluminescence in primary tumors
was also determined at 7, 21, and 39 days p.i. using the IVIS lumina II
system (PerkinElmer, Zaventem, Belgium). Mice were therefore injected
with 200 µl D-luciferin suspended in PBS (2 mg/100 µl; Gold Biotechnology,
St. Louis, MO) and images were acquired 10min later under inhalation
anesthesia (mixture of oxygen and isoflurane (2–3%)). At 39 days p.i., mice
were injected i.p. with 60mg/kg pimonidazole hydrochloride (Hypoxyp-
robe, Burlington, Massachusetts, USA) in 0.9% NaCl, which allows for
hypoxia assessment on isolated primary tumors through immunohisto-
chemistry. Primary tumors, spleens, and metastases-bearing organs,
including axillary lymph nodes, lungs, and liver, were isolated 1–2 h later
by first sedating the mice using a mixture of 100mg/kg ketamine
(Ketamidor, Ecuphar nv/sa, Oostkamp, Belgium) and 10mg/kg xylazine
(xylazini hydrochloridum, Val d’Hony-Verdifarm, Beringen, Belgium)
followed by sacrification of the mice through cervical dislocation. Primary
tumors and spleens were weighed using a digital weighing scale following
isolation. IVIS measurements and subsequent analysis using the living
image analysis software 3.2 allowed to quantify 4T1-luc-derived biolumi-
nescence in the primary tumors and isolated organs.
Measurement of cytokine and protein levels
Primary tumors and spleens were homogenized, mixed with 300 μl lysis
buffer supplemented with protease inhibitors (1% Nonidet P-40, 10 mM
Tris-HCl at pH 7.4, 200mM NaCl, 5 mM EDTA, 10% glycerol, 100 μM
phenylmethylsulfonyl, 1 mM oxidized L-glutathione (all from Sigma-
Aldrich), 0.15 μM aprotinin, and 2.1 μM leupeptin (Roche, Mannheim,
Germany)), and lysed ON at −20 °C. Samples were centrifuged the
following day at 17,000 × g for 1 h at 4 °C and the lysates were obtained
from the supernatant. Protein concentrations in the latter were measured
using the Bradford Protein Assay (Bio-Rad, Hercules, CA) and spectro-
photometry (Multiskan GO, Thermo Scientific) and diluted to 5 μg/μl with
lysis buffer. Blood was harvested through cardiac puncture, clotted, and
centrifuged at 17,000 × g for 1 h at 4 °C to obtain serum. A Proteome
Profiler Mouse XL Cytokine Array (Bio-Techne, Minneapolis, MN, USA) using
200 µg primary tumor lysates was used according to the manufacturer’s
instructions. A ChemiDoc MP Imaging System (Bio-Rad) was used for
detection and the data were analyzed in ImageJ. Relative protein
concentrations were obtained by subtraction of the background staining
and subsequent normalization to positive controls on the membrane. Ten
cytokines (BAFF, G-CSF, IFN-γ, IL-1β, IL-4, IL-6, IL-10, MCP-1, MIP-2, and TNF-
α) and two additional immune checkpoint proteins (CTLA-4 and PD-1)
were quantified in primary tumor lysates (50 μg protein) using the Luminex
Multiplex Assay (ProcartaPlex from Thermo Fisher Scientific) according to
the manufacturer’s instructions. ELISA was used to measure the levels of
CHI3L1 and LCN2 (Mouse Quantikine ELISA Kit, Bio-Techne) in primary
tumor lysates, sera and spleen lysates, Tie-2 levels (Mouse Quantikine ELISA
Kit, Bio-Techne) in both primary tumor lysates and sera, and granzyme B
(Mouse precoated ELISA Kit, Thermo Fisher Scientific), TGF-β1 levels
(Mouse uncoated ELISA Kit, Thermo Fisher Scientific), as well as VEGF levels
(Mouse Quantikine ELISA Kit, Bio-Techne) in primary tumor lysates
according to the manufacturer’s instructions. For ELISA measurements,
absorbances at 450 and 550 nm (the latter subtracted from the former for
correction purposes) were obtained using a microplate reader (Multiskan
GO, Thermo Scientific) and analyses were performed with Deltasoft.
Histology and immunohisto/cytochemistry
Isolated tissues (primary tumors, axillary lymph nodes, lungs, and livers)
were fixed in buffered 3.5% formaldehyde for 24 h at RT and embedded in
paraffin wax. Sections of 5 µm were deparaffinized, hydrated, and stained
with H&E. Sections were then dehydrated and mounted.
For immunohistochemical stainings, antigen retrieval was performed on
deparaffinized sections with Tris-EDTA buffer (10mM Tris, 1 mM EDTA
(Thermo Fisher Scientific); for cytokeratin 5, CTLA-4, c-MET, and pan-
cytokeratin), pH 9 or citrate buffer (10 mM tri-sodium citrate (Santa Cruz
Biotechnology, Heidelberg, Germany); for all other targets), pH 6 with
0.05% Tween-20 (Sigma-Aldrich) at 95 °C for 30min using a pressurized
Decloaking Chamber NxGen (Biocare Medical, CA, USA). The slides were
then cooled down to RT for 30min, treated with 0.06% (for CD8a) or 3% (all
other targets) H2O2 in methanol for 10min to block endogenous
peroxidase activity and with levamisole (2 mM in dH2O, only for dual
staining immunohistochemistry) to block alkaline phosphatase activity,
followed by a serum-free protein block (Dako, Heverlee, Belgium)
treatment for 10min to block nonspecific binding sites. For immunocy-
tochemical staining, culture medium was aspirated from the slide
chambers, cultured cells were fixed using 3.7% paraformaldehyde and
permeabilized by applying ice cold methanol for 4 min. The slides were
then rinsed with Tris-buffered saline (TBS, Biocare Medical) and incubated
with 5% BSA (Sigma-Aldrich) in TBS for 30min.
The next steps were identical for immunohistochemical and immuno-
cytochemical staining. More specifically, the slides were stained with
primary antibodies diluted in Antibody Diluent (Dako) for 1 h at RT and
secondary antibodies (ready-to-use) for 30min at RT. The used primary
antibodies and dilutions were: anti-cytokeratin 5 (1:100, clone EP1601Y,
Abcam, Cambridge, UK), anti-Ki67 (1:50, clone SP6; Thermo Fisher
Scientific), anti-pan-cytokeratin (1:100, polyclonal, Abcam), anti-CD11b
(1:4000, clone EPR1344, Abcam), anti-CD163 (1:500, clone EPR19518,
Abcam), anti-Ly6G (1:1000; clone 1A8; BioLegend, CA, USA), anti-CD8a
(1:50, clone 4SM15, Thermo Fisher Scientific), anti-granzyme B (1:1000,
polyclonal, Abcam), anti-PD-1 (1:1000, clone EPR20665, Abcam), anti-CTLA-
4 (1:500, clone CAL49, Abcam), FITC-conjugated anti-pimonidazole (1:25;
clone 4.3.11.3; Hypoxyprobe), anti-CAIX (1:1000; clone NB100–417; Novus
Biologicals, Littleton, CO, USA), anti-CD31 (1:2000; clone EPR17259; Abcam),
anti-α-SMA (1:2000, clone EPR5368, Abcam), anti-PDGFR-β (1:500, clone
Y92, Abcam), anti-Ang-1 (1:500, polyclonal, Abcam), anti-cisplatin DNA-
adducts (1:50, clone ICR4, Sigma-Aldrich), and anti-cleaved caspase 3
(1:1000, clone 5A1E, Cell Signaling Technology, Leiden, The Netherlands).
The used secondary antibodies were: Rat-on Mouse HRP-Polymer (Biocare
Medical) for Ly6G, CD8a, and cisplatin DNA-adducts, and Dako EnVision+
Rabbit (Dako) for cytokeratin 5, Ki67, pan-cytokeratin, CD11b, CD163,
granzyme B, PD-1, CTLA-4, CAIX, CD31, α-SMA, PDGFR-β, Ang-1, and
cleaved caspase 3. For visualization of HRP-positive staining, slides were
treated with a 3,3′-diaminobenzidine (DAB)-containing buffer (Dako) for
10min at RT. Counterstaining with hematoxylin was applied for 5 min at
RT, followed by dehydration of the tissue slides. Pimonidazole stainings did
not require a secondary antibody and was counterstained with DAPI
(0.4 µg/ml; Sigma-Aldrich) for 10min at RT. Mounting of the DAB-treated
and pimonidazole-stained slides was performed with Tissue-Tek Glas
mounting medium and antifading DABCO mounting medium, respectively.
For double staining immunohistochemistry, rat anti-CD31 (1:20, clone
SZ31, Dianova, Hamburg, Germany) and rabbit anti-α-SMA (1:2000, clone
EPR5368, Abcam) were simultaneously applied for 1 h at RT and the
DoubleStain IHC Kit: R&Rt on Human/Mouse Tissue (Green/HRP and AP/
Red) was used for the subsequent steps according to the manufacturer’s
instructions. Hematoxylin counterstain was not performed to allow
easier detection of codistribution (dark blue). All rinsing steps were
performed with TBS and were applied three times for 2 min at RT between
every incubation. Slides were incubated on an orbital shaker at 20 rpm
in a closed microscope box with TBS-wetted tissue paper for all blocking,
rinsing, and staining steps. Quantification of positive staining was
established using color deconvolution (for DAB and hematoxylin
counterstaining) or 8-bit image conversion (for pimonidazole stainings)
followed by automatic counting in ImageJ. Ki67 proliferation index was
calculated using ImageJS by capturing all nuclei and Ki67+ nuclei from
Ki67 stained primary tumor sections65.
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Western blot analyses
Primary tumor and 4T1 cell culture lysates were loaded on 12% Mini-
PROTEAN TGX Precast Protein Gels (Bio-Rad, CA, USA) at 25 µg per lane.
Lysates from treated 4T1 cultures were prepared with the same lysis buffer
used to lyse isolated tissues, but was additionally supplemented with
phosphatase inhibitor cocktail 1 (Sigma-Aldrich) to ensure visualization of
phosphorylated proteins. Lysates from treated NCI-H441 cultures were
prepared with a heated buffer (10mM Tris pH 7.4, 1 mM sodium
orthovanadate, and 1% SDS) and diluted in commercial lysis buffer
(MesoScale Met Duplex Kit) and loaded on a Nu-Page gel (Invitrogen, CA,
USA) at 40 µg per lane. Proteins in all gels were electrophoretically
separated and transferred on to 0.45 µm nitrocellulose membrane (Bio-
Rad). All further steps were performed on a shaking platform. Either freshly
prepared blocking buffer (TBS with 0.1% Tween-20 and 5% nonfat dry
milk) or commercial odyssey blocking buffer (only for NCI-H441 lysates; Li-
COR bioscience, Bad Homburg, Germany) was applied for 1 h at RT and
membranes were then incubated with primary antibody (diluted in
blocking buffer) ON at 4 °C. The used primary antibodies and dilutions
were: anti-c-MET (1:1000, clone 25H2, Cell Signaling Technology; or 1:1000,
clone EP1454Y, Abcam), anti-phospho-c-MET (Tyr1230/1234/1235; 1:1000,
polyclonal, Thermo Fisher Scientific), anti-phospho-Gab2 (Tyr452; 1:1000,
polyclonal, Cell Signaling Technology), anti-phospho-Akt (Ser473; 1:2000,
clone D9E or 1:1000, polyclonal for NCI-H441 lysates, both from Cell
Signaling Technology), anti-phospho-MEK1/2 (Ser217/221, 1:1000, poly-
clonal, Cell Signaling Technology), anti-phospho-p44/42 MAPK (Erk1/2;
Thr202/Tyr204; 1:2000, clone D13.14.4E or 1:1000, clone E10 for NCI-H441
lysates, both from Cell Signaling Technology), anti-β-actin (1:5000, clone
AC-15, Sigma-Aldrich), anti-Ang-2 (1:500, polyclonal, Novus Biologicals),
anti-cleaved caspase 3 (1:1000, clone 5A1E, Cell Signaling Technology), and
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:5000, clone
EPR16891, HRP-conjugated, Abcam). Washing of the membranes was
performed the following day with blocking buffer (three times, 5 min each)
prior to incubation of the membranes with secondary antibody (diluted in
blocking buffer) for 1 h at RT. The used secondary antibodies were as
follows: anti-mouse IgG, HRP-linked antibody (1:3000, Cell Signaling
Technology) for c-MET (Cell Signaling Technology); donkey anti-rabbit
IgG HRP-conjugated polyclonal antibody (1:10000, Thermo Fisher Scien-
tific) for c-MET (Abcam), phospho-Akt (clone D9E), phospho-p44/42 MAPK
(Erk1/2, clone D13.14.4E), Ang-2 and cleaved caspase 3; goat anti-mouse
IgG (H+ L) Alexa Fluor 680-conjugated polyclonal antibody (1:1000,
Thermo Fisher Scientific) for c-MET (Cell Signaling Technology, only for
NCI-H441 lysates) and phospho-p44/42 MAPK (Erk1/2, clone E10); goat
anti-rabbit IgG (H+ L) Alexa Fluor 680-conjugated polyclonal antibody
(1:1000, Thermo Fisher Scientific) for phospho-c-MET, phospho-Gab2
(polyclonal), phospho-Akt (polyclonal), phospho-MEK1/2 (polyclonal); and
donkey anti-mouse IgG (H+ L) IRDye 800-conjugated polyclonal antibody
(1:1000, Rockland Inc., PA, USA) for β-actin. Following another washing
step with blocking buffer (three times, 5 min each) and with dH2O (one
time, 5 min), protein bands were detected on the membranes using the
SuperSignal West Femto Kit (Thermo Fisher Scientific) on the ChemiDoc
MP Imaging System or scanned on the odyssey (only for NCI-H441 lysates).
Pageruler Prestained Protein Ladder (Thermo Fisher Scientific), Precision
Plus Protein Dual Color Standards (Bio-Rad), and MagicMark (Invitrogen)
provided molecular weight markers on the membranes and allowed to
determine the size of the detected protein bands. Quantification of the
signals was performed with ImageJ. Full images of all western blots and
corresponding molecular weight markers are shown in the Supplementary
information (Supplementary Figs. 12–17).
Statistical analyses
Statistics were performed using Prism (GraphPad). Data normalization was
performed through log10 normalization if necessary. P values were
calculated by one-way analysis of variance tests followed by
Newman–Keuls or Tukey’s post hoc test for multiple comparisons.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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